Cart
sales@molnova.com
Resiniferatoxin
CAS No. 57444-62-9
Resiniferatoxin( RTX | [3H]resiniferatoxin )
Catalog No. M28009 CAS No. 57444-62-9
Resiniferatoxin inhibits the production of Th1 cytokines, contributing to the defense against T. spiralis infection, and can be used in studies about the modulator of the immune response.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 1311 | In Stock |
|
| 5MG | 1074 | In Stock |
|
| 10MG | 1454 | In Stock |
|
| 100MG | Get Quote | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameResiniferatoxin
-
NoteResearch use only, not for human use.
-
Brief DescriptionResiniferatoxin inhibits the production of Th1 cytokines, contributing to the defense against T. spiralis infection, and can be used in studies about the modulator of the immune response.
-
DescriptionResiniferatoxin inhibits the production of Th1 cytokines, contributing to the defense against T. spiralis infection, and can be used in studies about the modulator of the immune response.
-
In Vitro——
-
In Vivo——
-
SynonymsRTX | [3H]resiniferatoxin
-
PathwayApoptosis
-
TargetIL Receptor
-
RecptorHOXA9
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number57444-62-9
-
Formula Weight628.71
-
Molecular FormulaC37H40O9
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (79.53 mM)
-
SMILESC[C@H]1[C@]23[C@]([C@@]4([C@](C(C)=C)(C1)O[C@](CC5=CC=CC=C5)(O2)O4)[H])(C=C(COC(CC6=CC(OC)=C(O)C=C6)=O)C[C@@]7(O)[C@]3(C=C(C)C7=O)[H])[H]
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Sonoda Y, Itoh M, Tohda S. Effects of HOXA9 Inhibitor DB818 on the Growth of Acute Myeloid Leukaemia Cells. Anticancer Res. 2021 Apr;41(4):1841-1847.
molnova catalog
related products
-
Mogroside IIe
Mogroside IIe is a major bioactive component of unripe S. grosvenorii fruit that downregulates the IL-9/IL-9 receptor pathway.
-
Secukinumab
Secukinumab is a fully humanized monoclonal anti-IL-17A antibody and the first in its class to be approved by the US Food and Drug Administration for the treatment of moderate to severe plaque psoriasis.
-
Dersalazine
Dersalazine (Dersalazine Free Base), an inhibitor of platelet-activating factor, exerts intestinal anti-inflammatory activity in different rodent types of colitis by down-regulating IL-17 expression, with potential efficacy in patients with ulcerative colitis.
